๐ฌDeep Research
NBIX โ Neurocrine Biosciences ยท catalysts, narrative & risks
Neurocrine Biosciences (NBIX) โ Point-in-Time Review (as of 2026-10-04)
Recent catalysts (last ~1โ3 months)
Q2 2026 earnings (reported July 30, 2026) is the dominant recent catalyst. Total revenue rose 39% year-over-year to $959 million, well above the Zacks Consensus Estimate of ~$901.5 million, and adjusted (non-GAAP) EPS came in at $2.85 versus consensus estimates ranging from ~$2.10โ$2.26 depending on the provider [1], [2], [12], [14]. This beat was broad-based:
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ